Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04828551 · ClinicalTrials.gov registry record · NA
Noninvasive Biomarkers of Metabolic Liver Disease 1.1
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 40
- Enrollment target
NCT04828551: Completed NA study, sponsored by Massachusetts General Hospital.
NCT04828551 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04828551, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 40 participants
- Enrollment target
Study Summary
NIMBLE is a comprehensive collaborative effort to standardize, compare, validate, and advance the regulatory qualification of imaging and circulating biomarkers to diagnose and stage nonalcoholic steatohepatitis (NASH), and to predict and assess response to therapeutic intervention (https://fnih.org/what-we-do/biomarkers-consortium/programs/nimble). This study focuses on estimating the repeatability and reproducibility of ultrasound elastography-based biomarkers across a range of fibrosis stages.
Interventions
- OTHER Physical measurements
- DIAGNOSTIC_TEST Blood collection
- DEVICE Ultrasound based shear wave speed and fat quantification methods
- OTHER Clinical history and medication reviews
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2021-03-18 |
| Est. Completion | 2021-11-20 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04828551
The ClinicalTrials.gov registry entry for NCT04828551 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Physical measurements is the first listed.
NCT04828551 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04828551 about?
NCT04828551 is a clinical study titled "Noninvasive Biomarkers of Metabolic Liver Disease 1.1". NIMBLE is a comprehensive collaborative effort to standardize, compare, validate, and advance the regulatory qualification of imaging and circulating biomarkers to diagnose and stage nonalcoholic steatohepatitis (NASH), and to predict and assess response to therapeutic intervention (https://fnih.org...
What is the current status of trial NCT04828551?
This trial is currently completed. It is a NA study. The enrollment target is 40 participants. The study started on 2021-03-18. Estimated completion is 2021-11-20.
What interventions are being tested in trial NCT04828551?
The interventions under investigation include: Physical measurements (OTHER), Blood collection (DIAGNOSTIC_TEST), Ultrasound based shear wave speed and fat quantification methods (DEVICE), Clinical history and medication reviews (OTHER).
Who is sponsoring clinical trial NCT04828551?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.